News and Announcements
Actinogen Medical Ltd (ASX: ACW) XanADu Phase II study gains five new USA study sites
- Published July 08, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- XanADu opens five additional study sites in the USA, having a total of 25 sites across the USA, Australia and the UK.
- The new sites are set to accelerate patient enrollment in the study.
- The study is on the efficacy of Xanamen in treating patients with mild Alzheimer’s Disease.
Actinogen Medical (ASX: ACW), a biotech company, has announced the opening of five additional study sites in the USA to its international XanADu study. The sites are for the XanADu Phase II double-blind trials of Xanamen in mild Alzheimer’s Disease. The USA has the highest potential patient population interested in participating in an Alzheimer’s clinical trial. The sites have committed to identifying and screening patients to enrol in the trial, ensuring the study continues to complete patient enrollment by the end of 2018, with the initial results expected in Q2 2019.
XanADu is a Phase II 12-week, randomised, placebo-controlled study being carried out in an additional 20 sites in Australia, the UK and the USA, with 117 patients enrolled to date. The trial will assess the tolerability and efficacy of Xanamen in subjects with mild dementia due to Alzheimer’s disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory and other hallmarks of Alzheimer’s disease. Xanamen blocks the activity of 11β-HSD1, an enzyme that converts inactive cortisone into its active form, cortisol in the brain. Blocking the activity of the enzyme, therefore, reduces the amount of cortisol in the brain.
About Actinogen Medical Ltd
Actinogen Medical Limited (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
